

**10<sup>th</sup> Anniversary Kidney Cancer Program Symposium**  
**March 29<sup>th</sup> 2023**  
**Agenda**

Introduction	8.00	8.10	Jim Brugarolas	Welcome and introduction
	8.10	8.15	Payal Kapur	Renal cancer, staging and subtypes
	8.15	8.20	Mara Conacci Sorrell	The nucleolus: key to grading aggressiveness
	8.20	8.25	Ivan Pedrosa	Radiological assessment of renal cancer
	8.25	8.30	Jeff Cadeddu	Surgery for renal cancer: when, what, and how
	8.30	8.35	Ananth Madhuranthakam	When kidney cancer metastasizes to the bone
	8.35	8.40	Raouib Hannan	Radiation for renal cancer: when, what, and how
	8.40	8.45	Tian Zhang	Overview of drug therapy
Hypoxia Signaling and the Epigenome	8.50	8.55	Payal Kapur	Introduction to clear cell renal cell carcinoma (ccRCC)
	8.55	9.00	Peter Ly	Chromothripsis in ccRCC
	9.00	9.05	Qing Zhang	VHL signaling and HIF
	9.05	9.10	Satwik Rajaram	Towards a digital pathological classification
	9.10	9.15	Jing Wang	Radiogenomics
	9.15	9.20	Jim Brugarolas	Targeting HIF2: first and second-generation inhibitors
	9.20	9.25	Xiankai Sun	Visualizing HIF2 in tumors
	9.25	9.30	Daniel Siegwart	Endogenous targeting of SORT LNPs to kidney tumors
	9.30	9.35	Laura Banaszynski	Chromatin dysregulation in kidney cancer
	9.35	9.40	Ram Mani	The 3D genome architecture of kidney cancer
9.40	9.45	Weibo Luo	Targeting epigenetic vulnerabilities in ccRCC	
9.45	9.50	Ralph Mason	Targeting hypoxia in tumors	
DISCUSSION				
BREAK				
Invasion, Transformation and Latency	10.40	10.45	Srinivas Malladi	Drivers of invasion in RCC
	10.45	10.50	Kevin Dean	Light-sheet microscopy to identify earliest metastatic colonization events
	10.50	10.55	Payal Kapur	Genomic drivers of tumor latency
	10.55	11.00	Srinivas Malladi	Biology of latency
	11.00	11.05	Jenna Jewell	mTOR in renal cancer
	11.05	11.10	Yingfei Wang	PARP in renal cancer
	11.10	11.15	Payal Kapur	RCC transformation and EMT
	11.15	11.20	Tom Carroll	Hippo/Warts signaling in sarcomatoid RCC
	11.20	11.25	Jin Jiang	Targeting Hippo signaling for ccRCC therapy
	11.25	11.30	Qian Cong	Protein-protein interactions in kidney cancer
DISCUSSION				
Immunology	11.50	11.55	Chen Yao	The TME of RCC
	11.55	12.00	Andrew Sandstrom	Inflammation in renal cancer
	12.00	12.05	Janie Qin	PD-L1 imaging to predict immunotherapy response
	12.05	12.10	Lindsay Cowell	T cell repertoire analyses in RCC
	12.10	12.15	Tuoqi Wu	Understanding humoral immunity in ccRCC
	12.15	12.20	Kiyoshi Arizumi	Acquired resistance to RCC immunotherapy
	12.20	12.25	Andrew Koh	The microbiome, ICIs, and renal cancer
12.25	12.30	Chuo Chen	New chemical tools for RCC	
DISCUSSION				
LUNCH				
Metabolism	1.50	1.55	Kevin Courtney	Kidney cancer and metabolism
	1.55	2.00	Jin Ye	Lipid accumulation in ccRCC
	2.00	2.05	Gerta Hoxhaj	Purine synthesis pathways in physiology and cancer
	2.05	2.10	Guiyang Hao	SGLT-2 as a diagnostic target for kidney cancer: beyond 18F-FDG PET
	2.10	2.15	Ralph DeBerardinis	Targeting metabolism in renal cancer
	2.15	2.20	Prashant Mishra	Mitochondrial alterations in renal cancer
	2.20	2.25	David McFadden	Targeting mitochondrial defects in cancer
	2.25	2.30	Puneeth Iyengar	A comprehensive model to study cancer cachexia
	2.30	2.35	Jeffrey Zigman	Ghrelin and cachexia
2.35	2.40	Ian Corbin	SCARB1 for lipoprotein-based drug delivery in RCC	
DISCUSSION				
tRCC and Wilms tumors	3.00	3.05	Jim Brugarolas	tRCC: insights from a novel mouse model
	3.05	3.10	Ben Sabari	Phase separation in tRCC
	3.10	3.15	Kenneth Chen	DROSHA mutations in Wilms tumor
	3.15	3.20	Ivan Dorso	KAP1 in kidney development and tumorigenesis
	3.20	3.25	Keri Drake	Defining the cell type of origin in Wilms Tumor
3.25	3.30	Maddy Artunduaga	Radiomics and radiogenomics in Wilms tumor	
DISCUSSION				
BREAK				
Resources	4.20	4.25	Alana Christie	Kidney Cancer Explorer
	4.25	4.30	Hua Zhong	Genomics
	4.30	4.35	Vanina Toffessi Tcheuyap	Tumorgrafts
	4.35	4.40	Debabrata Saha	Small animal imaging
	4.40	4.45	Payal Kapur	Histology core facility
	4.45	4.50	Bruce Posner	Robotic screens
DISCUSSION				
Clinical Trials	5.05	5.15	Tian Zhang	Investigator initiated/consortium trials
Dinner Program			Carlos Bagley Tu Dan	
	5.15	5.40	Aurelie Garant Torral Patel Robert Timmerman	Challenges: Brain and spine metastases
			Bonnie Bermas Meghan Heberton	
	5.45	6.10	Sasan Mirfakhraee Katie Rascon Vlad Zaha	Immune-related adverse events and their management
			Waddah Arafat	
	6.15	6.40	Laura Howe-Martin Stephanie Terauchi	Caring for RCC patients across the continuum
			Hans Hammers	
6.45	7.05	Tian Zhang	Pressing questions and opportunities	
		James Brugarolas		
7.05	7.15		Final Remarks	